Related Experiment Videos
Antigen-based immunointervention in human autoimmune diseases.
1BioXell, Via Olgettina 58, 20132 Milan, Italy. luciano.adorini@bioxell.com
Trends in Biotechnology
|October 20, 2004
Summary
Oral administration of autoantigen peptides shows promise for treating autoimmune diseases like rheumatoid arthritis by modulating immune responses. This immunointervention strategy inhibits harmful Th1 cells and promotes beneficial Th2 and regulatory T cells.
Area of Science:
- Immunology
- Autoimmune Diseases
- Therapeutic Strategies
Background:
- Antigen administration offers potential mechanisms to ameliorate autoimmune diseases.
- Strategies like regulatory T cell induction and immune deviation are effective in experimental models.
- Translating these findings to human autoimmune diseases, particularly rheumatoid arthritis, remains a key challenge.
Purpose of the Study:
- To investigate the clinical efficacy of mucosal autoantigen administration in human autoimmune diseases.
- To evaluate immune deviation following oral autoantigen peptide administration in rheumatoid arthritis patients.
Main Methods:
- Oral administration of a disease-related peptide to rheumatoid arthritis patients.
- Assessment of immune responses, including T helper cell subsets and regulatory T cells.
Main Results:
- Clear-cut immune deviation was observed following oral peptide administration.
- Inhibition of Th1 responses was noted.
- Enhancement of Th2 and Foxp3-positive regulatory T cell populations was observed.
Conclusions:
- Oral autoantigen administration can induce beneficial immune deviation in rheumatoid arthritis.
- This immunointervention strategy holds potential for treating human autoimmune diseases.
- Further research is warranted to establish clinical efficacy.